The aggregated data showed a significantly lower rate of heart failure in patients treated with SGLT2 inhibitors than in those treated with placebo (RR: 0.73; 95% CI 0.64–0.84; p < 0.00001; high SOE). The gene discussed is SLC5A2; the disease is heart failure.